ReviewFrontiers in oncology2020
Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 63 citations in OpenAlex.
- Stimuli-Responsive Nanocarriers as Next-Generation on-Demand Drug Delivery Systems for Cancer Therapy: Mechanistic Insights, Trigger Modalities, and Translational Challenges.Pharmaceutics · 2026Review
- One-Step Microfluidic Manufactured Fucose-Decorated Sweetosomes Choose the Time and the Road for Their Intracellular Journey to Cancer Treatment.Advanced healthcare materials · 2026Article
- Review
- Engineering and evaluation of precision-glycosylated clickable albumin nanoplatform for targeting the tumor microenvironment.Theranostics · 2026Article
- Advances in active targeting of ligand-directed polymeric nanomicellesRSC advances · 2024Review
- Galactose: A Versatile Vector Unveiling the Potentials in Drug Delivery, Diagnostics, and Theranostics.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments.Pharmaceutics · 2024Review
- Systematic Investigation of Cellular Response to Hydroxyl Group Orientation Differences on Gold Glyconanoparticles.ACS omega · 2023Article
- Glucose-conjugated glutenin nanoparticles for selective targeting and delivery of camptothecin into breast cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Delivery of Therapeutic miRNA via Plasma-Polymerised Nanoparticles Rescues Diabetes-Impaired Endothelial Function.Nanomaterials (Basel, Switzerland) · 2023Article
- Review
- Sulfation of Heparan and Chondroitin Sulfate Ligands Enables Cell-Specific Homing of Nanoprobes.Chemistry (Weinheim an der Bergstrasse, Germany) · 2023Article
- Dendrimers as Modifiers of Inorganic Nanoparticles for Therapeutic Delivery in Cancer.Pharmaceutics · 2023Review
- Polymeric nanoparticles targeting Sialyl-Tn in gastric cancer: A live tracking under flow conditions.Materials today. Bio · 2022Article
- Mucosomes: Intrinsically Mucoadhesive Glycosylated Mucin Nanoparticles as Multi-Drug Delivery Platform.Advanced healthcare materials · 2022Article
- Beyond GalNAc! Drug delivery systems comprising complex oligosaccharides for targeted use of nucleic acid therapeutics.RSC advances · 2022Review
- Biological chemotaxis-guided self-thermophoretic nanoplatform augments colorectal cancer therapy through autonomous mucus penetration.Science advances · 2022Article
- Nanocarriers for anticancer drugs: Challenges and perspectives.Saudi journal of biological sciences · 2022Review
- Glycans as Targets for Drug Delivery in Cancer.Cancers · 2022Review
- PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoparticles (NPs) are novel platforms that can carry both cancer-targeting molecules and drugs to avoid severe side effects due to nonspecific drug delivery in standard chemotherapy treatments. Cancer cells are characterized by abnormal membranes, metabolic changes, the presence of lectin receptors, glucose transporters (GLUT) overexpression, and glycosylation of immune receptors of programmed death on cell surfaces. These characteristics have led to the development of several strategies for cancer therapy, including a large number of carbohydrate-modified NPs, which have become desirable for use in cell-selective drug delivery systems because they increase nanoparticle-cell interactions and uptake of carried drugs. Currently, the potential of NP glycosylation to enhance the safety and efficacy of carried therapeutic antitumor agents has been widely acknowledged, and much information is accumulating in this field. This review seeks to highlight recent advances in NP stabilization, toxicity reduction, and pharmacokinetic improvement and the promising potential of NP glycosylation from the perspective of molecular mechanisms described for drug delivery systems for cancer therapy. From preclinical proof-of-concept to demonstration of therapeutic value in the clinic, the challenges and opportunities presented by glycosylated NPs, with a focus on their applicability in the development of nanodrugs, are discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.